Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Neuroligin-1 Signaling Controls LTP and NMDA Receptors by Distinct Molecular Pathways.

Wu X, Morishita WK, Riley AM, Hale WD, Südhof TC, Malenka RC.

Neuron. 2019 May 8;102(3):621-635.e3. doi: 10.1016/j.neuron.2019.02.013. Epub 2019 Mar 11.

PMID:
30871858
2.

Long-Term Diabetic Microenvironment Augments the Decay Rate of Capsaicin-Induced Currents in Mouse Dorsal Root Ganglion Neurons.

Chen X, Duan Y, Riley AM, Welch MA, White FA, Grant MB, Obukhov AG.

Molecules. 2019 Feb 21;24(4):775. doi: 10.3390/molecules24040775.

3.

The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.

Chen X, Taylor-Nguyen NN, Riley AM, Herring BP, White FA, Obukhov AG.

J Neuroinflammation. 2019 Jan 31;16(1):21. doi: 10.1186/s12974-019-1407-6.

4.

Inositol hexakisphosphate increases the size of platelet aggregates.

Brehm MA, Klemm U, Rehbach C, Erdmann N, Kolšek K, Lin H, Aponte-Santamaría C, Gräter F, Rauch BH, Riley AM, Mayr GW, Potter BVL, Windhorst S.

Biochem Pharmacol. 2019 Mar;161:14-25. doi: 10.1016/j.bcp.2018.12.011. Epub 2018 Dec 14.

5.

A Fluorescent Probe Identifies Active Site Ligands of Inositol Pentakisphosphate 2-Kinase.

Whitfield H, Gilmartin M, Baker K, Riley AM, Godage HY, Potter BVL, Hemmings AM, Brearley CA.

J Med Chem. 2018 Oct 11;61(19):8838-8846. doi: 10.1021/acs.jmedchem.8b01022. Epub 2018 Sep 19.

PMID:
30160967
6.

A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate.

Riley AM, Unterlass J, Konieczny V, Taylor CW, Helleday T, Potter BVL.

Medchemcomm. 2018 Jul 1;9(7):1105-1113. doi: 10.1039/C8MD00149A. Epub 2018 Jun 4.

7.

Simple synthesis of 32P-labelled inositol hexakisphosphates for study of phosphate transformations.

Whitfield H, Riley AM, Diogenous S, Godage HY, Potter BVL, Brearley CA.

Plant Soil. 2018 Jun;427(1-2):149-161. doi: 10.1007/s11104-017-3315-9. Epub 2017 Jun 27.

8.

Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.

Li W, Chen X, Riley AM, Hiett SC, Temm CJ, Beli E, Long X, Chakraborty S, Alloosh M, White FA, Grant MB, Sturek M, Obukhov AG.

Basic Res Cardiol. 2017 Sep;112(5):54. doi: 10.1007/s00395-017-0643-0. Epub 2017 Jul 29.

9.

Molecular Determinants of the Sensitivity to Gq/11-Phospholipase C-dependent Gating, Gd3+ Potentiation, and Ca2+ Permeability in the Transient Receptor Potential Canonical Type 5 (TRPC5) Channel.

Chen X, Li W, Riley AM, Soliman M, Chakraborty S, Stamatkin CW, Obukhov AG.

J Biol Chem. 2017 Jan 20;292(3):898-911. doi: 10.1074/jbc.M116.755470. Epub 2016 Dec 5.

10.

Association Between Storage Interval and Contamination of Reprocessed Flexible Endoscopes in a Pediatric Gastrointestinal Procedural Unit.

Scanlon P, Flaherty K, Reilly EA, Barth EG, Potter-Bynoe G, Cardini J, Riley AM, McAdam AJ, Sandora TJ.

Infect Control Hosp Epidemiol. 2017 Feb;38(2):131-135. doi: 10.1017/ice.2016.260. Epub 2016 Nov 7.

PMID:
27817757
11.

A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion.

Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BV, Brennan CH, Maffucci T, Larijani B, Falasca M.

Sci Rep. 2016 May 20;6:26142. doi: 10.1038/srep26142.

12.

Insights into the activation mechanism of class I HDAC complexes by inositol phosphates.

Watson PJ, Millard CJ, Riley AM, Robertson NS, Wright LC, Godage HY, Cowley SM, Jamieson AG, Potter BV, Schwabe JW.

Nat Commun. 2016 Apr 25;7:11262. doi: 10.1038/ncomms11262.

13.

Synthetic tools for studying the chemical biology of InsP8.

Riley AM, Wang H, Shears SB, L Potter BV.

Chem Commun (Camb). 2015 Aug 14;51(63):12605-8. doi: 10.1039/c5cc05017k.

14.

Designer small molecules to target calcium signalling.

Swarbrick JM, Riley AM, Mills SJ, Potter BV.

Biochem Soc Trans. 2015 Jun;43(3):417-25. doi: 10.1042/BST20140293. Review.

PMID:
26009185
15.

Synthetic inositol phosphate analogs reveal that PPIP5K2 has a surface-mounted substrate capture site that is a target for drug discovery.

Wang H, Godage HY, Riley AM, Weaver JD, Shears SB, Potter BV.

Chem Biol. 2014 May 22;21(5):689-99. doi: 10.1016/j.chembiol.2014.03.009. Epub 2014 Apr 24.

16.

PKC-dependent Phosphorylation of the H1 Histamine Receptor Modulates TRPC6 Activity.

Chen X, Egly C, Riley AM, Li W, Tewson P, Hughes TE, Quinn AM, Obukhov AG.

Cells. 2014 Apr 4;3(2):247-57. doi: 10.3390/cells3020247.

17.

Human genome-wide RNAi screen identifies an essential role for inositol pyrophosphates in Type-I interferon response.

Pulloor NK, Nair S, McCaffrey K, Kostic AD, Bist P, Weaver JD, Riley AM, Tyagi R, Uchil PD, York JD, Snyder SH, García-Sastre A, Potter BV, Lin R, Shears SB, Xavier RJ, Krishnan MN.

PLoS Pathog. 2014 Feb 27;10(2):e1003981. doi: 10.1371/journal.ppat.1003981. eCollection 2014 Feb. Erratum in: PLoS Pathog. 2014 Mar;10(3):e1004095. PLoS Pathog. 2014 Oct;10(10):e1004519. McCaffrey, Kathleen [added].

18.

Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel.

Chen X, Sun W, Gianaris NG, Riley AM, Cummins TR, Fehrenbacher JC, Obukhov AG.

J Biol Chem. 2014 Apr 4;289(14):9600-10. doi: 10.1074/jbc.M113.536862. Epub 2014 Feb 25.

19.

Cellular internalisation of an inositol phosphate visualised by using fluorescent InsP5.

Riley AM, Windhorst S, Lin HY, Potter BV.

Chembiochem. 2014 Jan 3;15(1):57-67. doi: 10.1002/cbic.201300583. Epub 2013 Dec 6.

20.

Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by adenophostin A and its analogues.

Saleem H, Tovey SC, Riley AM, Potter BV, Taylor CW.

PLoS One. 2013;8(2):e58027. doi: 10.1371/journal.pone.0058027. Epub 2013 Feb 28.

21.

Regioselective opening of myo-inositol orthoesters: mechanism and synthetic utility.

Godage HY, Riley AM, Woodman TJ, Thomas MP, Mahon MF, Potter BV.

J Org Chem. 2013 Mar 15;78(6):2275-88. doi: 10.1021/jo3027774. Epub 2013 Mar 5.

22.

Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by analogues of IP3.

Saleem H, Tovey SC, Rahman T, Riley AM, Potter BV, Taylor CW.

PLoS One. 2013;8(1):e54877. doi: 10.1371/journal.pone.0054877. Epub 2013 Jan 25.

23.

Subtype-selective regulation of IP(3) receptors by thimerosal via cysteine residues within the IP(3)-binding core and suppressor domain.

Khan SA, Rossi AM, Riley AM, Potter BV, Taylor CW.

Biochem J. 2013 Apr 15;451(2):177-84. doi: 10.1042/BJ20121600.

24.

Fibrinogen - a possible extracellular target for inositol phosphates.

Grint T, Riley AM, Mills SJ, Potter BV, Safrany ST.

Messenger (Los Angel). 2012 Dec 1;1(2):160-166.

25.

Inframolecular acid-base and coordination properties towards Na(+) and Mg(2+) of myo-inositol 1,3,4,5,6-pentakisphosphate: a structural approach to biologically relevant species.

Veiga N, Torres J, Macho I, Gómez K, Godage HY, Riley AM, Potter BV, González G, Kremer C.

Dalton Trans. 2013 May 7;42(17):6021-32. doi: 10.1039/c2dt31807e.

26.

Physiological evidence consistent with reduced neuroplasticity in human adolescents born preterm.

Pitcher JB, Riley AM, Doeltgen SH, Kurylowicz L, Rothwell JC, McAllister SM, Smith AE, Clow A, Kennaway DJ, Ridding MC.

J Neurosci. 2012 Nov 14;32(46):16410-6. doi: 10.1523/JNEUROSCI.3079-12.2012.

27.

First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase.

Riley AM, Wang H, Weaver JD, Shears SB, Potter BV.

Chem Commun (Camb). 2012 Nov 28;48(92):11292-4. doi: 10.1039/c2cc36044f.

28.

Determination of neo- and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy.

Turner BL, Cheesman AW, Godage HY, Riley AM, Potter BV.

Environ Sci Technol. 2012 May 1;46(9):4994-5002. doi: 10.1021/es204446z. Epub 2012 Apr 20.

29.

A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery.

Mills SJ, Persson C, Cozier G, Thomas MP, Trésaugues L, Erneux C, Riley AM, Nordlund P, Potter BV.

ACS Chem Biol. 2012 May 18;7(5):822-8. doi: 10.1021/cb200494d. Epub 2012 Feb 27.

30.

Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A.

Sureshan KM, Riley AM, Thomas MP, Tovey SC, Taylor CW, Potter BV.

J Med Chem. 2012 Feb 23;55(4):1706-20. doi: 10.1021/jm201571p. Epub 2012 Feb 8.

31.

Selective determinants of inositol 1,4,5-trisphosphate and adenophostin A interactions with type 1 inositol 1,4,5-trisphosphate receptors.

Rossi AM, Sureshan KM, Riley AM, Potter VL, Taylor CW.

Br J Pharmacol. 2010 Nov;161(5):1070-85. doi: 10.1111/j.1476-5381.2010.00947.x.

32.

Binding of inositol 1,4,5-trisphosphate (IP3) and adenophostin A to the N-terminal region of the IP3 receptor: thermodynamic analysis using fluorescence polarization with a novel IP3 receptor ligand.

Ding Z, Rossi AM, Riley AM, Rahman T, Potter BV, Taylor CW.

Mol Pharmacol. 2010 Jun;77(6):995-1004. doi: 10.1124/mol.109.062596. Epub 2010 Mar 9.

33.

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.

Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, Maffucci T.

Br J Cancer. 2010 Jan 5;102(1):104-14. doi: 10.1038/sj.bjc.6605408.

34.

Adenophostins: High-Affinity Agonists of IP(3) Receptors.

Rossi AM, Riley AM, Potter BV, Taylor CW.

Curr Top Membr. 2010;66:209-33. doi: 10.1016/S1063-5823(10)66010-3. Epub 2010 Jul 25. No abstract available.

PMID:
22353482
35.

Developments in tissue culture detection of respiratory viruses.

McAdam AJ, Riley AM.

Clin Lab Med. 2009 Dec;29(4):623-34. doi: 10.1016/j.cll.2009.07.009. Review.

PMID:
19892224
36.

Synthetic partial agonists reveal key steps in IP3 receptor activation.

Rossi AM, Riley AM, Tovey SC, Rahman T, Dellis O, Taylor EJ, Veresov VG, Potter BV, Taylor CW.

Nat Chem Biol. 2009 Sep;5(9):631-9. doi: 10.1038/nchembio.195. Epub 2009 Aug 9.

37.

The behaviour of inositol 1,3,4,5,6-pentakisphosphate in the presence of the major biological metal cations.

Veiga N, Torres J, Godage HY, Riley AM, Domínguez S, Potter BV, Díaz A, Kremer C.

J Biol Inorg Chem. 2009 Sep;14(7):1001-13. doi: 10.1007/s00775-009-0510-z. Epub 2009 May 5.

38.

Activation of IP(3) receptors by synthetic bisphosphate ligands.

Sureshan KM, Riley AM, Rossi AM, Tovey SC, Dedos SG, Taylor CW, Potter BV.

Chem Commun (Camb). 2009 Mar 14;(10):1204-6. doi: 10.1039/b819328b. Epub 2009 Feb 4.

39.

Favorable outcome after aggressive treatment of infection in a diabetic patient with MRSA-related IgA nephropathy.

Riley AM, Wall BM, Cooke CR.

Am J Med Sci. 2009 Mar;337(3):221-3. doi: 10.1097/MAJ.0b013e318184a4a1.

PMID:
19204555
40.

Restructuring trauma wards to reduce patient stay.

Riley AM, Teall J, Quinn B, Wallace J, Doyle A.

Nurs Times. 2008 Mar 11-17;104(10):29. No abstract available.

PMID:
18416399
41.
42.

scyllo-inositol pentakisphosphate as an analogue of myo-inositol 1,3,4,5,6-pentakisphosphate: chemical synthesis, physicochemistry and biological applications.

Riley AM, Trusselle M, Kuad P, Borkovec M, Cho J, Choi JH, Qian X, Shears SB, Spiess B, Potter BV.

Chembiochem. 2006 Jul;7(7):1114-22.

43.

On the contribution of stereochemistry to human ITPK1 specificity: Ins(1,4,5,6)P4 is not a physiologic substrate.

Riley AM, Deleu S, Qian X, Mitchell J, Chung SK, Adelt S, Vogel G, Potter BV, Shears SB.

FEBS Lett. 2006 Jan 9;580(1):324-30. Epub 2005 Dec 19.

44.

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.

Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Broggini M, Iacobelli S, Potter BV, Innocenti P, Falasca M.

Cancer Res. 2005 Sep 15;65(18):8339-49.

45.

Interaction of the catalytic domain of inositol 1,4,5-trisphosphate 3-kinase A with inositol phosphate analogues.

Poinas A, Backers K, Riley AM, Mills SJ, Moreau C, Potter BV, Erneux C.

Chembiochem. 2005 Aug;6(8):1449-57.

PMID:
15997461
46.

Regulation of casein kinase-2 (CK2) activity by inositol phosphates.

Solyakov L, Cain K, Tracey BM, Jukes R, Riley AM, Potter BV, Tobin AB.

J Biol Chem. 2004 Oct 15;279(42):43403-10. Epub 2004 Aug 5.

47.

Human metapneumovirus in children tested at a tertiary-care hospital.

McAdam AJ, Hasenbein ME, Feldman HA, Cole SE, Offermann JT, Riley AM, Lieu TA.

J Infect Dis. 2004 Jul 1;190(1):20-6. Epub 2004 Jun 2.

PMID:
15195239
49.
50.

Dimers of D-myo-inositol 1,4,5-trisphosphate: design, synthesis, and interaction with Ins(1,4,5)P3 receptors.

Riley AM, Laude AJ, Taylor CW, Potter BV.

Bioconjug Chem. 2004 Mar-Apr;15(2):278-89.

PMID:
15025523

Supplemental Content

Loading ...
Support Center